Chemspace and LabNetwork collaborate to extend access to chemical databases

14 Feb 2019

Collaboration provides drug discovery researchers access to European distribution and local support for library of in-stock and on-demand compounds.

Chemspace and LabNetwork, a WuXi AppTec company, both online marketplaces for chemical compounds used in drug discovery, have entered into a collaboration agreement. Under the agreement, LabNetwork’s products will be available on www.chem-space.com, with distribution and technical support provided by Chemspace for European customers. The collaboration expands the market reach of both companies to pharma and biotech companies.

Chemspace and LabNetwork collaborate to extend access to chemical databases

The Chemspace database encompasses over 100 million unique chemical building blocks, fragments and screening compounds, and is the world’s largest library of purchasable chemicals. The online catalogue includes in-stock and make-on-demand molecules, offering an easy, fast way to search using a broad range of filter options, such as substructure, similarity, and by using various text identifiers.

Use of the Chemspace database is free-of-charge for customers. There are no licence fees for users to review and access the platform. Chemspace invites global chemistry suppliers, ranging from small to large organizations, to upload their catalogues to the site, to provide an efficient solution for buyers when sourcing chemicals.

Dr Yurii Moroz, CEO at Chemspace, commented: “The collaboration with LabNetwork will provide drug discovery scientists, medicinal chemists, and academic researchers access to a vast diversity of high-quality products. We see a lot of synergy in our companies combining forces both from a business perspective and also to improve availability of compounds to the research community. Ultimately to shorten the drug discovery process in the hope of finding better cures for patients, quicker.”

Read More

Related news

Eisai collaborates with University of Dundee on cancer drug discovery

Eisai collaborates with University of Dundee on cancer drug discovery

10 Jul 2019

It is hoped that research into PROTACs will lead to new drug discoveries for proteins present in cancer, which are difficult to treat with conventional small molecule inhibitors.

Read more 
Fresh data on protein interactions in Alzheimer’s disease

Fresh data on protein interactions in Alzheimer’s disease

2 Jul 2019

Demonstrates the unique ability of diffusional sizing to assess protein binding in-solution and for difficult-to-study systems.

Read more 
Cyclolab Ltd strengthens its position in the market

Cyclolab Ltd strengthens its position in the market

1 Jul 2019

Cyclolab Ltd. is an R&D and cGMP manufacturing company focusing on all aspects of cyclodextrin science, manufacturing and applications for cyclodextrin, Dexolve, Sugammadex, formulation development, custom synthesis, Niemann Pick C.

Read more 
Inaugural Bio Integrates conference highlights industry's inefficiency in developing products

Inaugural Bio Integrates conference highlights industry's inefficiency in developing products

18 Jun 2019

Industry leaders give voice to issues and trends shaping the biotech sector, including the importance of collaboration.

Read more 
Clinical supply milestone reached for triple-negative breast cancer treatment

Clinical supply milestone reached for triple-negative breast cancer treatment

12 Jun 2019

PhoenixMD and WuXi STA have produced a multikilogram drug supply for PMD-026 under GMP manufacturing practices.

Read more 
Trial finds vitamin D does not prevent type 2 diabetes in people at high risk

Trial finds vitamin D does not prevent type 2 diabetes in people at high risk

11 Jun 2019

No meaningful difference between the two study groups regardless of age, sex, race or ethnicity.

Read more 
Partnership seeks breath biomarkers for the early detection of malignant mesothelioma

Partnership seeks breath biomarkers for the early detection of malignant mesothelioma

6 Jun 2019

Owlstone Medical and IAHFIAW to use Breath Biopsy to examine the chemicals found on the breath of individuals with documented historical exposure to asbestos and radiologically and histologically confirmed mesothelioma.

Read more 
Lilly gets its hands on non-opioid pain asset

Lilly gets its hands on non-opioid pain asset

4 Jun 2019

Early-phase molecule from Centrexion to be developed further as a potential non-opioid treatment option for multiple pain conditions.

Read more 
Updated clinical trial simulation software saves time and money

Updated clinical trial simulation software saves time and money

3 Jun 2019

One customer saves $25m and 3 years' development time in their clinical development strategy.

Read more 
Merck bolsters oncology pipeline with acquisition

Merck bolsters oncology pipeline with acquisition

22 May 2019

Acquisition includes novel late-stage renal cell carcinoma candidate, PT2977.

Read more